- Report
- October 2024
- 193 Pages
Global
From €3360EUR$3,545USD£2,807GBP
€3733EUR$3,939USD£3,119GBP
- Report
- February 2025
- 240 Pages
Global
From €2550EUR$2,690USD£2,130GBP
- Report
- January 2025
- 135 Pages
Global
From €2843EUR$2,999USD£2,375GBP
- Report
- May 2024
- 133 Pages
Global
From €6160EUR$6,499USD£5,146GBP
- Clinical Trials
- December 2024
- 60 Pages
Global
From €1422EUR$1,500USD£1,188GBP
- Report
- October 2024
- 210 Pages
Global
From €7535EUR$7,950USD£6,295GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €2643EUR$2,789USD£2,208GBP
- Report
- November 2023
- 139 Pages
Global
From €4218EUR$4,450USD£3,524GBP
- Report
- August 2022
- 117 Pages
Global
From €4265EUR$4,500USD£3,563GBP
- Report
- January 2024
- 395 Pages
Global
From €7109EUR$7,500USD£5,939GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1422EUR$1,500USD£1,188GBP
- Report
- February 2024
- 77 Pages
Global
From €3500EUR$3,956USD£3,026GBP
- Report
- April 2025
- 50 Pages
Global
From €2512EUR$2,650USD£2,098GBP
- Book
- July 2009
- 1116 Pages

Oxcarbazepine is a medication used to treat epilepsy and other seizure disorders. It is a member of the anticonvulsant class of drugs, which work by reducing the abnormal electrical activity in the brain that causes seizures. Oxcarbazepine is also used to treat bipolar disorder and neuropathic pain. It is available in both immediate-release and extended-release formulations.
Oxcarbazepine is a relatively new anticonvulsant, first approved by the US Food and Drug Administration in 2000. It is generally well-tolerated, with fewer side effects than some of the older anticonvulsants. It is also less likely to cause drug interactions than other anticonvulsants.
Oxcarbazepine is used in combination with other anticonvulsants to treat epilepsy and other seizure disorders. It is also used as a mood stabilizer in the treatment of bipolar disorder. In addition, it is used to treat neuropathic pain, a type of chronic pain caused by nerve damage.
Several pharmaceutical companies manufacture and market oxcarbazepine, including GlaxoSmithKline, Novartis, Mylan, and Teva Pharmaceuticals. Show Less Read more